NEW DELHI: Glenmark Pharmaceuticals Ltd has initiated phase 3 clinical trials in India on the use of generic antiviral drug favipiravir for treatment of mild to moderate covid-19, a study which the Mumbai-based drug-maker expects to complete by August.
Drug Controller General of India V.G. Somani had in late April approved Glenmark’s plan to conduct phase 3 trials on the use of the drug.
Clinical trials have commenced and over 10 leading government & private hospitals in India are being enrolled for the study, the company said in an exchange filing.
Favipiravir is a generic version of Avigan of Japan’s Fujifilm Toyama Chemical Co Ltd, a subsidiary of Fujifilm Corporation.